RankingsPricing
  1. US-listed companies
  2. Travere Therapeutics, Inc.

Travere Therapeutics, Inc.TVTX

Market cap
$1.1B
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Feb 29,
2012		Dec 31,
2012		Dec 31,
2013		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Product---------211201128
License---------171118
Total revenue---100134155164175198227212145
Product-----------8
License-----------3
Cost of goods sold------6567811
Research and development--------132210236245
Selling, general and administrative-1508093101104129136150220266
Change in fair value of contingent consideration-------1542215-
Restructuring-----4-0----11
Acquired IPR&D expense--------97---
Total operating expenses14,825------313374389479533
Total operating expenses14,825------313374389479533
Operating loss---23,972,073-51-58-54-80-137-176-162-267-388
Interest income-------1052622
Interest expense----8-1-1----20-11-11
Other income, net----0-01-0-01012
Loss on extinguishment of debt----4---17----8-
Total other income (expense), net---1561-5-22-9-13-18-1212
Interest income-------1052622
Interest expense----8-1-1----20-11-11
Other income, net----0-01-0-01012
Loss on extinguishment of debt----4---17----8-
Total other income (expense), net---1561-5-22-9-13-18-1212
Loss from continuing operations before income tax provision---33,747,734105-58-58-102-146-189-180-278-376
Income tax provision on continuing operations--75,775-12-1011-0-19000
Net loss-14,825-30,343,856-33,823,509117-48-60-103-146-169-180-278-111
Loss from continuing operations, net of tax-0.14-----------376
Earnings Per Share, Basic---3.49-1.29-1.54-2.54---3.01-4.37-1.5
Income from discontinued operations, net of tax-----------265
Earnings Per Share, Diluted---3.17-1.29-1.54-2.54---3.01-4.37-1.5
Net loss-14,825-30,343,856-33,823,509117-48-60-103-146-169-180-278-111
Income (Loss) from Continuing Operations, Per Basic Share------------5.07
Income (Loss) from Continuing Operations, Per Diluted Share------------5.07
Net income from discontinued operations, basic (in dollars per share)-----------3.57
Net income from discontinued operations, diluted (in dollars per share)-----------3.57
Net income (loss) per common share, basic (in dollars per share)---3.49-1.29-1.54-2.54---3.01-4.37-1.5
Net income (loss) per common share, diluted (in dollars per share)---3.17-1.29-1.54-2.54---3.01-4.37-1.5
Net loss-14,825-30,343,856-33,823,509117-48-60-103-146-169-180-278-111
Unrealized loss on defined benefit pension plan----------00
Foreign currency translation (loss) gain-------0-121-2
Unrealized gain (loss) on marketable debt securities---109,987-50-0-12-0-1-24
Comprehensive loss---33,933,496112-48-60-103-144-171-180-281-110
Net loss-14,825-30,343,856-33,823,509117-48-60-103-146-169-180-278-111
Unrealized loss on defined benefit pension plan----------00
Foreign currency translation (loss) gain-------0-121-2
Unrealized gain (loss) on marketable debt securities---109,987-50-0-12-0-1-24
Comprehensive loss---33,933,496112-48-60-103-144-171-180-281-110